RET and thyroid cancer: Clinical studies have determined that Lenvatinib blocks VEGF- and FGF-driven angiogenesis, KIT-dependent angiogenesis, RET-fusion/RET freak tumorigenesis, and VEGFR3-associated lymphangiogenesis in preclinical human thyroid cancer models [13].